Lung Cancer Trials Ask AI to find trials
TerminatedNot applicableNCT05812274
Official study title

Apricity CARE to Improve ICI Outcomes of Ethnic/Racial Minority NSCLC Patients

Study summary

The purpose of this trial is to study the effectiveness of the AprictyRxTM care service to improve treatment outcomes of ethnic/racial minority N.S.C.L.C. patients receiving standard of care immunotherapy, and reduce the frequency of healthcare system interactions.

Ask AI to explain this study
Start here

Key things to know

Main goalSupportive Care

This describes the study’s primary purpose.

What is being studiedApricity C.A.R.E. Program for Cancer Adverse events Rapid Evaluation

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated May 5, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Interventional

Where is it offered?4 U.S. locations

Locations may change over time.

Who runs it?Columbia University

Study sponsor

01
Study overview

What this study is about

Purpose
Supportive Care
Study type
Interventional
Phase
Not applicable
Sponsor
Columbia University
Interventions being studied
Other: Apricity C.A.R.E. Program for Cancer Adverse events Rapid Evaluation
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Treatment approach
Immunotherapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Age≥ 18 years
  • Confirmed NSCLC diagnosis
  • Prescribed treatment with immune-checkpoint inhibitor, including in combination with chemotherapy
  • Ability to understand and the willingness to sign a written informed consent document
  • Self-identification as a member of an ethnic minority or underserved population.
Reasons someone may not be able to joinExclusion criteria
  • An individual with presence of any medical, psychological, or social condition that, in the opinion of the investigator would preclude participation in this study.
  • Patients enrolled in other interventional clinical trials at the time of screening will be excluded.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Montefiore Health CenterNew York, New York
  • Mount Sinai School of MedicineNew York, New York
  • NYU Medical CenterNew York, New York
  • Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer CenterNew York, New York

Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 5, 2026. Always confirm current availability with the study team.

View original record ↗